Sanchit Kumar

PGY4 @HopkinsHeart
Interests: Stats, EP, critical care
Via @PennIMResidents @YaleMed @AIIMS_nd @MAMC_NewDelhi
Coffee aficionado and random trivia enthusiast

[Sanchit Kumar @sanchitkumarMD]

@AgrimaMianMD @jamecancerdoc @BrianHill_MDPhD @paolocaimiMD @AchintyaSinghMD @AjayMian @shivenmian @DrSumanMian @MSKCancerCenter @PICIatMSK @ASH_hematology That's amazing! Congratulations!!

[Sanchit Kumar @sanchitkumarMD]

@drkarthik2010 @JAMA_current @drjohnm Congratulations to you and the team, sir! Wonderful trial!

[F. Perry Wilson, MD MSCE @fperrywilson]

It's always bothered me that medical research papers are static. A PDF, showing you what the authors thought were the important findings.
I think we're ready for a paradigm shift and I did a little proof of concept...

[Sanchit Kumar @sanchitkumarMD]

@ManikGIMD Amazing news - they're lucky to have you! Congratulations!!

[Sanchit Kumar @sanchitkumarMD]

@ShubhamMehtaGI Congratulations, Mehtay! Well done!!

[Sanchit Kumar @sanchitkumarMD]

@maniratneshSS Thank you so much, brother! You've been a constant source of strength and encouragement through everything! You're the best!

[Sanchit Kumar @sanchitkumarMD]

Summary-
Good data to help guide therapeutic decisions regarding AC beyond the initial 6mo in patients with active cancer. Evidence supports a low dose apixaban regimen in this setting.

[Sanchit Kumar @sanchitkumarMD]

Clinically relevant bleeding - 12.1% vs 15.6% (sHR 0.75, 0.58-0.97) was also reassuring.
Equivalence was also shown in rates of major bleeding, all-cause mortality and other safety/efficacy endpoints.

[Sanchit Kumar @sanchitkumarMD]

They also enrolled different kinds of cancer, cancer treatments, ECOG status and different initial AC regimens that improve generalizability.
However, race/ethnicity data was not collected and f/u was upto 12mo only. ~20% had Rx <6mo but this was balanced b/w arms.

[Sanchit Kumar @sanchitkumarMD]

A total of 1766 (866 to 2.5mg, 900 to 5mg) patients were randomized with similar characteristics at baseline.

Recurrent VTE occurred in 2.1% (2.5mg) vs 2.8% (5mg), with sHR 0.76 (0.41-1.41) at a median Rx duration of 11.8mo. The sHR was below the non-inferiority margin

[Sanchit Kumar @sanchitkumarMD]

Patients with active cancer are at a high risk of thrombosis.

While indefinite AC is recommended for proximal DVT/PE in this population, this is confounded by a high bleeding risk.

Can a lower dose of DOACs beyond 6mo help?

[Sanchit Kumar @sanchitkumarMD]

Primary outcome was recurrent VTE analyzed using a Fine-Gray model (due to death being a competing risk), with a pre-specified sub-hazard (sHR) non-inferiority margin of 2.00 for the upper bound of the 95% CI

[Sanchit Kumar @sanchitkumarMD]

API-CAT was a double-blind, non-inferiority RCT that enrolled patients w/proximal DVT of lower extremities or >=segmental pulmonary embolism AFTER completing 6mo of AC.
Patients were randomized to reduced dose (2.5mg) vs full dose (5mg) apixaban twice daily and followed for 1y

[Abinet Aklilu @Nephronette]

Incredibly humbled and honored to receive this award in honor of the inspiring physician scientist Iva Dostanic & for the opportunity to share our prelim data & ongoing RCT of SGLT2i in acute CRS. I'm so grateful to my mentor @fperrywilson, patients, AHA @YaleNephrology @YaleIMed

[Sanchit Kumar @sanchitkumarMD]

@ShubhamMehtaGI Well done! Congratulations and great work, @ShubhamMehtaGI and team!!

[Sanchit Kumar @sanchitkumarMD]

@AvinainderSingh @RonBlankstein @BrighamFellows @MassGenBrigham @BWHIntCard @Ajar_Kochar @OzanUnluMD Amazing as always! Congratulations and great work!!

[Sanchit Kumar @sanchitkumarMD]

@maniratneshSS @chirayumohin @NatureCancer Great work, @chirayumohin !!

[Yale Internal Medicine @YaleIMed]

Researchers have identified a biomarker panel that improves the assessment of chronic kidney disease (CKD) progression in children.

Learn more about the research.

@YaleNephrology @YalePediatrics @JasonHenryG @fperrywilson
https://t.co/4TiDDcp9lz

[Sanchit Kumar @sanchitkumarMD]

@LovedeepDhingra @YaleMed Congratulations and well done, Lovedeep!!